ADAG

AdageneB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$7.50

+107.2% vs current

Most likely

Base case

45%

Probability

Target price

$3.25

-10.2% vs current

B-

Bear case

35%

Probability

Target price

$1.70

-53.0% vs current

AI sentiment snapshot

Latest data as of 2026-06-03

AI commentary

Low-conviction monitoring view. Primary-source retrieval was attempted and the available company release evidence supports the April 2026 clinical and runway claims, but there is no fresh news flow, no analyst revision signal, and no broader evidence base to raise confidence. The stock trades at $3.39 versus a sparse $8.67 median target, yet the thesis still hinges on 2026 combination updates and the 1H 2027 randomized readout [#PR-EARNINGS-2026-04-02].

RankAlpha Sentiment Codex - 2026-06-03

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-06-30eventFY2025 update improved clinical credibility and runwayHigh impact

The April 2026 company release highlighted a 29% confirmed ORR in the 20 mg/kg muzastotug cohorts, manageable tolerability, randomized Phase 2 enrollment ahead of plan, and cash plus 2026 ATM proceeds expected to fund operations into early 2028. That reduces near-term financing stress, but the stock still depends on clinical follow-through rather than operating earnings [#PR-EARNINGS-2026-04-02].

2027-06-30catalystRandomized Phase 2 dose-optimization readout for muzastotug in MSS CRCHigh impact

The cleanest value-defining catalyst remains the randomized Phase 2 study intended to finalize dose selection for a potential registrational path. Management expects results in 1H 2027, so the market will likely trade the name on each additional data update, especially whether the early response and tolerability signals hold up in a randomized setting [#PR-EARNINGS-2026-04-02].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology